SynthesisCurrent allergy and asthma reports2025
Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis.
Synthesis in Current allergy and asthma reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease.Clinical and translational allergy · 2026Review
- Does Patient-Reported Olfactory Improvement Correlate with Quality of Life and Polyp Size Reduction in Patients with CRSwNP Treated with Dupilumab?Medicines (Basel, Switzerland) · 2026Article
- Could Dupilumab Improve Sleep Quality in CRSwNP Patients: Myth or Reality? A Systematic Review.Journal of clinical medicine · 2026Review
- Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes.International forum of allergy & rhinology · 2026Article
- Mucosal Remodeling in Chronic Rhinosinusitis with Nasal Polyps: The Role of Innate Lymphoid Cells and Reprogramming Under IL-4Rα Blockade.International journal of molecular sciences · 2026Review
- Impact of dupilumab on SNOT-22 domain and individual item scores in chronic rhinosinusitis with nasal polyps.Scientific reports · 2025Article
- Recent Developments in Monoclonal-Antibody-Based Biologic Therapy for Severe Refractory Eosinophilic Asthma.Antibodies (Basel, Switzerland) · 2025Review
- Evaluation of extended dupilumab dosing intervals Q2W (biweekly) versus Q4W (monthly) in chronic rhinosinusitis with nasal polyposis: a real-world study from Saudi Arabia : Extended dupilumab dosing in CRSwNP.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- A Literature Review of the Management of Nasal Polyps: Biologics Combined With Endoscopic Surgery.Cureus · 2025Review
- Predictive value of tissue eosinophilia for dupilumab response in chronic rhinosinusitis with nasal polyps: A retrospective monocentric study.The World Allergy Organization journal · 2025Article
- Remission in chronic rhinosinusitis with nasal polyps treated with biologics: a real-life experience.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewChronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating inflammatory condition that significantly impacts quality of life. Despite treatment advances, recurrence is common, prompting the exploration of novel therapies such as monoclonal antibodies targeting the type 2 immune response, notably dupilumab. This research aims to evaluate the real-world evidence (RWE) of dupilumab in treating severe CRSwNP, comparing sinonasal outcomes to those observed in randomized clinical trials. RECENT
findingsSignificant improvements were noted, with the average SNOT-22 score reduction being 37.2 points post-dupilumab treatment. The nasal polyp size (NPS) showed an average decrease of 3.6 points. The analysis highlighted the practical effectiveness of dupilumab, emphasizing its benefit over conventional therapies in reducing NPS and improving nasal symptoms. The findings advocate for the integration of dupilumab into standard treatment protocols for severe CRSwNP, providing a robust alternative that could potentially reduce the high recurrence rates associated with current management strategies. This study underscores the utility of RWE in assessing the effectiveness of new medical treatments, suggesting that dupilumab offers substantial real-world benefits for patients suffering from this challenging condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.